Skip to main content

Table 2 Clinical responses of third-generation EGFR-TKI as second line therapy in NSCLC patients with EGFR 19delins and EGFR 19del

From: Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

  19delins (n = 8) 19del (n = 10) P value
ORR, n (%) 5 (62.5) 3 (30.0) 0.34
DCR, n (%) 8 (100.0) 8 (80.0) 0.48
Best objective response, n (%)
 CR 0 0  
 PR 5 (62.5) 3 (30.0)  
 SD 3 (37.5) 5 (50.0)  
 PD 0 2 (20.0)  
  1. CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease, ORR Objective response rate, DCR Disease control rate